NARF

Across TCGA pan-cancer cohorts, NARF mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NARF data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NARF mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NARF expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

PDAC, UCEC, and LUAD are the cancer types where NARF mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.259	0.519	<.001	79	view →
UCEC	DFS	Median	II,III,IV	0.946	0.467	.002	48	view →
LUAD	OS	Median	II,III,IV	0.303	0.853	.001	16	view →
LSCC	OS	Quartile	All	0.928	0.709	.011	7	view →
HNSC	DFS	Median	All	0.767	0.317	.045	6	view →
GBM	OS	Median	All	0.291	0.490	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NARF–PDAC (DFS)

Open the PDAC breakdown →